Skip to Main Content

Author Details

Jerald P Radich
Fred Hutchinson Cancer Center
1989
344
89
PMIDPaper TitleJournal TitlePublished Year
37534515Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia.Haematologica2024
38086008CML and the WHO: Why?J Clin Oncol2024
37706363Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies.Haematologica2024
37935977A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.Leukemia2024
36927800Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients.Biomark Res2023
37794101European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia.Leukemia2023
37699001Rapid detection of myeloid neoplasm fusions using single-molecule long-read sequencing.PLOS Glob Public Health2023
37495373The (near) miracle of therapy in chronic myeloid leukaemia.Br J Haematol2023
37088793Management of chronic myeloid leukemia in 2023 - common ground and common sense.Blood Cancer J2023
37021537Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research Network.Haematologica2023
37467017Ultrasensitive chimerism enhances measurable residual disease testing after allogeneic hematopoietic cell transplantation.Blood Adv2023
37034683Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia.medRxiv2023
37267439Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis.Blood Adv2023
36421011Allogeneic transplantation for chronic myeloid leukemia: I'm not dead yet!Am J Hematol2023
36938892Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia.Leuk Lymphoma2023
36790617CML Outcomes and Care Delivery During the COVID-19 Pandemic in Low- and Middle-Income Countries.Curr Hematol Malig Rep2023
36727397Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis.Haematologica2023
34775030Ultrasensitive Quantitation of Genomic Chimerism by Single-Molecule Molecular Inversion Probe Capture and High-Throughput Sequencing of Copy Number Deletion Polymorphisms.J Mol Diagn2022
35511672Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia.Haematologica2022
35767897International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.Blood2022
35420676TTMV-RARA fusion as a recurrent cause of AML with APL characteristics.Blood Adv2022
35658498Management of Myeloproliferative Neoplasms in the Molecular Era: From Research to Practice.Am Soc Clin Oncol Educ Book2022
35388063AKR1C3 expression in T acute lymphoblastic leukemia/lymphoma for clinical use as a biomarker.Sci Rep2022
35073168Precision Medicine in Low- and Middle-Income Countries.Annu Rev Pathol2022
35298544Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR::ABL1 monitoring in chronic myelogenous leukemia.PLoS One2022
35229572Another Philadelphia story.Haematologica2022
34491344Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors.J Natl Cancer Inst2022
34780648MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β-chain cytokine receptor endocytosis.Blood2022
32617974Molecular testing of chronic myeloid leukaemia in low resource areas.Br J Haematol2021
33712039Analysis of the gap in PCR monitoring availability for patients with chronic myeloid leukemia in 60 low- and middle-income countries.Cost Eff Resour Alloc2021
33707652Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial.Leukemia2021
33657787Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021.Haematologica2021
34425749A graphical, interactive and GPU-enabled workflow to process long-read sequencing data.BMC Genomics2021
34319086Capillary-Mediated Single-Cell Dispenser.Anal Chem2021
34292760Spectrum of BCR-ABL Mutations and Treatment Outcomes in Ethiopian Imatinib-Resistant Patients With Chronic Myeloid Leukemia.JCO Glob Oncol2021
33180106Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.JAMA Oncol2021
33175653Predictors of tyrosine kinase inhibitor adherence trajectories in patients with newly diagnosed chronic myeloid leukemia.J Oncol Pharm Pract2021
32127639European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.Leukemia2020
31637757Phase I/II multisite trial of optimally dosed clofarabine and low-dose TBI for hematopoietic cell transplantation in acute myeloid leukemia.Am J Hematol2020
31883804The minimal that kills: Why defining and targeting measurable residual disease is the "Sine Qua Non" for further progress in management of acute myeloid leukemia.Blood Rev2020
32592408Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies.Hematol Oncol2020
32817791AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report.Biomark Res2020
32218491Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia.Sci Rep2020
32265500Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study.Leukemia2020
32457305Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL.Blood Cancer J2020
32194289Targeted Sequencing Improves DIPSS-Plus Prognostic Scoring in Myelofibrosis Patients Undergoing Allogeneic Transplantation.Biol Blood Marrow Transplant2020
30643249PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.Nat Genet2019
31808889Meeting the needs of CML patients in resource-poor countries.Hematology Am Soc Hematol Educ Program2019
31533919New approaches to molecular monitoring in CML (and other diseases).Blood2019
30926392Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.Clin Lymphoma Myeloma Leuk2019
  • 1 - 50 of 344

Recommended Authors

Jessica Leonard
Oregon Health & Science University
Career Start Year 2015
Number of shared co-authors 23
Justin M Watts
University of Miami, Sylvester Comprehensive Cancer Center
Career Start Year 2014
Number of shared co-authors 27
Ann-Kathrin Eisfeld
The Ohio State University Comprehensive Cancer Center
Career Start Year 2011
Number of shared co-authors 25
Jennifer Dunlap
Oregon Health & Science University
Career Start Year 2008
Number of shared co-authors 17
Thomas K??hnke
Cancer Institute, Stanford University School of Medicine
Career Start Year 2008
Number of shared co-authors 4
Amanda Winters
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 1
Friedrich St??lzel
University Hospital TU Dresden
Career Start Year 2008
Number of shared co-authors 11
Felicitas Thol
Hannover Medical School
Career Start Year 2007
Number of shared co-authors 15
Paulo Vidal Campregher
Hospital Israelita Albert Einstein
Career Start Year 2007
Number of shared co-authors 5
Thomas Cluzeau
Universite Nice Cote d'azur, CHU de Nice
Career Start Year 2005
Number of shared co-authors 7
Marlise R Luskin
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 27
Ronan Swords
Oregon Health and Science University
Career Start Year 2004
Number of shared co-authors 31
Tara L Lin
University of Kansas Medical Center
Career Start Year 2004
Number of shared co-authors 23
Jean-Baptiste Micol
INSERM U7, Universite Paris-Saclay
Career Start Year 2004
Number of shared co-authors 11
Raphael Itzykson
Universite Paris Cite, INSERM, CNRS
Career Start Year 2004
Number of shared co-authors 12
Daniel A Pollyea
University of Colorado Division of Hematology
Career Start Year 2004
Number of shared co-authors 41
Christopher R Cogle
College of Medicine, University of Florida
Career Start Year 2003
Number of shared co-authors 26
Christoph R??llig
Hopp Children's Cancer Center (KiTZ)
Career Start Year 2000
Number of shared co-authors 15
Elie Traer
Oregon Health & Science University
Career Start Year 1998
Number of shared co-authors 28
Nikolas von Bubnoff
University Hospital of Schleswig-Holstein
Career Start Year 1997
Number of shared co-authors 6
Bruno C Medeiros
AbbVie Inc.
Career Start Year 1996
Number of shared co-authors 35
Brian J P Huntly
University of Cambridge
Career Start Year 1996
Number of shared co-authors 16
Thoralf Lange
Hospital Weissenfels
Career Start Year 1994
Number of shared co-authors 28
Michael Heuser
Hannover Medical School
Career Start Year 1993
Number of shared co-authors 21
Gautam Borthakur
MD Anderson Cancer Center
Career Start Year 1992
Number of shared co-authors 33
Michael W Becker
James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester
Career Start Year 1992
Number of shared co-authors 4
Claude Preudhomme
Lille University Hospital, INSERM UMR-S7, CNRS UMR9020, Lille University.
Career Start Year 1989
Number of shared co-authors 15
Robert H Collins
University of Texas Southwestern Medical Center
Career Start Year 1987
Number of shared co-authors 37
Clayton A Smith
University of Colorado, Aurora CO.
Career Start Year 1987
Number of shared co-authors 8
Torsten Haferlach
Taussig Cancer Institute, Cleveland Clinic
Career Start Year 1983
Number of shared co-authors 45

Collaborators

Derek L Stirewalt
Fred Hutchinson Cancer Center
Co-authored papers 40
Soheil Meshinchi
Fred Hutchinson Cancer Research Centre
Co-authored papers 34
Jorge Cortes
Georgia Cancer Center
Co-authored papers 32
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Co-authored papers 30
Vivian G Oehler
Fred Hutchinson Cancer Center.
Co-authored papers 26
Michael W Deininger
University of Utah Huntsman Cancer Institute
Co-authored papers 23
Dong Wook Kim
Yonsei University College of Medicine, Republic of Korea S. Biomedics Co.
Co-authored papers 22
Brian J Druker
Oregon Health & Science University
Co-authored papers 17
Neil P Shah
University of California San Francisco
Co-authored papers 16
Martin S Tallman
Memorial Sloan-Kettering Cancer Center
Co-authored papers 14
Daniel J DeAngelo
Dana-Farber Cancer Institute
Co-authored papers 13
Todd A Alonzo
Keck School of Medicine, University of Southern California
Co-authored papers 13
Jason Gotlib
Stanford University School of Medicine
Co-authored papers 10
Moshe Talpaz
University of Michigan Rogel Cancer Center.
Co-authored papers 9
Ravi Bhatia
University of Alabama at Birmingham
Co-authored papers 8
Dietger Niederwieser
University of Leipzig
Co-authored papers 7
Judy Kirk
Co-authored papers 7
Effie W Petersdorf
Fred Hutchinson Cancer Center
Co-authored papers 7
Stephen G O'Brien
Newcastle University
Co-authored papers 6
Richard M Stone
Dana Farber Cancer Institute
Co-authored papers 6
Suzanne Kamel-Reid
Toronto General Hospital, University Health Network, University of Toronto
Co-authored papers 6
Charles G Mullighan
St Jude Children's Research Hospital
Co-authored papers 5
Farhad Ravandi
University of Texas M.D. Anderson Cancer Center
Co-authored papers 5
Bret Helton
University of Washington
Co-authored papers 4
Steven M Kornblau
The University of Texas MD Anderson Cancer Center
Co-authored papers 4
Emily A Stevens
Clinical Research Division, Fred Hutchinson Cancer Research Center
Co-authored papers 4
George Q Daley
Boston Children's Hospital, Harvard Medical School
Co-authored papers 4
Kevin P Weinfurt
Center for Health Measurement, Duke University
Co-authored papers 4
Mignon L Loh
University of Washington
Co-authored papers 3
Rong Zeng
Co-authored papers 3
Release 1.2